1. Denmark Stocks

  2. •

    Commercial services

  3. •

    Miscellaneous commercial services
Gubra A/S

Gubra A/S

39.26
EUR
-1.88
(-4.57%)
723.75MMarket Cap
Mar 03Next Earn
Gubra A/S
FRA:PI3
(Frankfurt Stock Exchange)

Recent

price

39.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
DKK
- -
10.54
15.62
12.19
13.51
16.3
161.94
- -
Revenue per Share
- -
0.78
4.16
0.26
-2.93
-2.24
103.83
- -
Basic EPS, GAAP
- -
1.58
3.75
0.62
-4
-1.66
103.99
- -
Free Cash Flow per Basic Share
- -
- -
0.41
4.04
4.5
- -
61.43
- -
Dividend per Share
3.9
4.89
9.26
6.62
29.44
27.63
70.16
63.69
Book Value per Share
3.89
4.82
9.04
6.17
28.73
26.7
69.35
62.7
Tangible Book Value per Share
16
16
16
16
15
16
16
16
Basic Weighted Avg Shares
- -
172
255
199
205
266
2,637
- -
Sales/Revenue/Turnover
- -
9.21
34.73
-0.65
-23.25
-18.82
81.54
- -
Operating Margin (%)
- -
9
10
7
10
16
17
- -
Depreciation Expense
- -
13
68
4
-45
-36
1,691
- -
Net Income, GAAP
- -
7.23
22
31.14
- -
- -
21.54
- -
Effective Tax Rate (%)
- -
7.37
26.61
2.16
-21.72
-13.73
64.11
- -
Profit Margin (%)
37
54
103
98
458
402
1,075
943
Working Capital
50
52
46
61
61
82
89
158
LT Debt
64
80
151
108
480
451
1,146
1,046
Total Equity
- -
11.32
40.39
-0.46
- -
- -
187.37
- -
Return on Invested Capital (%)
- -
10.74
40.44
2.81
- -
- -
188.39
- -
Return on Capital (%)
- -
17.66
58.7
3.32
-15.15
-7.85
211.78
- -
Return on Common Equity (%)

Capital Structure

DKK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
15
19
29
LT Borrowings
- -
- -
- -
LT Finance Leases
78
89
158
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
7,916
8,471
5,409

Working Capital

DKK

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
2,782
1,160
1,034
Cash, Cash Equivalents & STI
2,722
1,083
901
Accounts Receivable, Net
38
35
30
Inventories
- -
- -
- -
Total Current Liabilities
1,617
85
90
Payables & Accruals
- -
- -
- -
ST Debt
15
19
29
Deferred Revenue
- -
- -
- -

Growth Rates

DKK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
110.46%
154.33%
Free Cash Flow
- -
-1,408.84%
-6,348.21%
Net Income, GAAP
- -
-1,108.28%
-4,731.94%
Sales/Revenue/Turnover
- -
190.2%
892.25%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
266
2025
- -
- -
2,637
2026
- -
- -
- -

Semi-annual Earnings Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.24
2025
- -
- -
103.83
2026
- -
- -
- -

Semi-annual Dividends Per Share

DKK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
61.43
2026
- -
- -
- -
Similar Companies
PayPal Holdings, Inc. (NASDAQ:PYPL)
Shopify Inc. (NASDAQ:SHOP)
Greenland Mines Ltd (NASDAQ:GRML)
Block, Inc. (NYSE:XYZ)
Netcapital Inc. (NASDAQ:NCPL)
Shopify, Inc. Class A (TSX:SHOP)
Business
Gubra A/S (GUBRA.CO) is a Denmark-based biotechnology company that specializes in high-end preclinical contract research organization (CRO) services and peptide-based drug discovery focused on metabolic and fibrotic diseases; its operations span Europe, North America and other international markets from headquarters in Hørsholm, Denmark, where it was founded in 2008. The company delivers comprehensive preclinical research solutions including in vivo pharmacology, ex vivo assays, drug profiling, pharmacokinetics, biomarker assays, bioinformatics, next-generation sequencing (NGS), 2D and 3D histology with artificial intelligence pathology, stereology, and whole brain and organ imaging; these services target disease areas such as liver (MASH), obesity, kidney (DKD/CKD/PKD/AKI), diabetes, central nervous system (CNS), lung (IPF), and non-rodent studies in miniature pigs, serving pharmaceutical and biotechnology clients including 16 of the top 20 global pharmaceutical companies. Gubra organizes activities into two synergistic segments: CRO Services, which generates steady cash flow through specialized preclinical studies in translatable rodent and non-rodent models, and Discovery & Partnerships (D&P), which identifies and develops peptide-based drug candidates like amylin analogs and urocortin-2 (UCN2) programs for obesity for potential partnering with development milestone payments and royalties. Recent developments include a March 2025 license agreement with AbbVie granting global rights to develop GUB014295, a long-acting amylin analog for obesity treatment, providing a $350 million upfront payment and up to $1.875 billion in milestones; ongoing partnerships with Boehringer Ingelheim for obesity, Hemab ApS for bleeding disorders, and seven active collaborations overall; preparation for a first-in-human study of its UCN2 obesity program in early 2026; maintenance of full-year 2025 CRO growth guidance at 20% amid solid European demand; and evaluation of merger, acquisition, and pipeline expansion opportunities using AbbVie proceeds.